CKD 942Alternative Names: CKD942
Latest Information Update: 15 Dec 2015
At a glance
- Originator Chong Kun Dang
- Class Antifibrotics
- Mechanism of Action Undefined mechanism
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity Yes
Highest Development Phases
- Phase II Idiopathic pulmonary fibrosis
Most Recent Events
- 15 Dec 2015 Phase-II clinical trials in Idiopathic pulmonary fibrosis in South Korea (unspecified route)